{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:45:45Z","timestamp":1761965145373,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41571-019-0291-4","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T12:05:58Z","timestamp":1571313958000},"page":"726-728","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunotherapy trials in mesothelioma \u2014 promising results, but don\u2019t stop here"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-9526","authenticated-orcid":false,"given":"Anna K.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"291_CR1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang, N. J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21, 2636\u20132644 (2003).","journal-title":"J. Clin. Oncol."},{"key":"291_CR2","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman, G. et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387, 1405\u20131414 (2016).","journal-title":"Lancet"},{"key":"291_CR3","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada, M. et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase II study in malignant pleural mesothelioma (MERIT). Clin. Cancer Res. 25, 5485\u20135492 (2019).","journal-title":"Clin. Cancer Res."},{"key":"291_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne, M. J. & Nowak, A. K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann. Oncol. 15, 257\u2013260 (2004).","journal-title":"Ann. Oncol."},{"key":"291_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley, E. W. et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 18, 623\u2013630 (2017).","journal-title":"Lancet Oncol."},{"key":"291_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst, M. J. et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 7, 260\u2013270 (2019).","journal-title":"Lancet Respir. Med."},{"key":"291_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel, A. et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 20, 239\u2013253 (2019).","journal-title":"Lancet Oncol."},{"key":"291_CR8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","volume":"13","author":"Y Metaxas","year":"2018","unstructured":"Metaxas, Y. et al. Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J. Thorac. Oncol. 13, 1784\u20131791 (2018).","journal-title":"J. Thorac. Oncol."},{"key":"291_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","volume":"6","author":"L Calabro","year":"2018","unstructured":"Calabro, L. et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir. Med. 6, 451\u2013460 (2018).","journal-title":"Lancet Respir. Med."},{"issue":"19","key":"291_CR10","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","volume":"25","author":"Raffit Hassan","year":"2019","unstructured":"Hassan, R. et al. Live-attenuated, listeria monocytogenes expressing mesothelin (crs-207) with chemotherapy for treatment of malignant pleural mesothelioma. Clin. Cancer Res. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0070\n\n (2019).","journal-title":"Clinical Cancer Research"},{"key":"291_CR11","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","volume":"33","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33, 1325\u20131333 (2015).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0291-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0291-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:43:10Z","timestamp":1684618990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0291-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["291"],"URL":"https:\/\/doi.org\/10.1038\/s41571-019-0291-4","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"type":"print","value":"1759-4774"},{"type":"electronic","value":"1759-4782"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"17 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K.N. has been a paid consultant or adviser for Bayer, Boehringer Ingelheim, MSD and Roche; has been a consultant or adviser with fees to her institution for Atara, Douglas and Pharmabcine; has received travel funding from AstraZeneca and Boehringer Ingelheim; and her institution receives research funding to institution from AstraZeneca and Douglas Pharmaceuticals. P.M.F. has been an unpaid consultant or adviser for Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), EMD Serono, Inivata, Janssen, Merck and Novartis, and his institution receives research funding from AstraZeneca, BMS, Corvus, Kyowa and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}